NLA Recommendations & Statements
The NLA released an official scientific statement on Lipoprotein(a) [Lp(a)] designed as a comprehensive source of guidance for medical professionals making decisions to improve the health and well-being of children and adults at risk of premature cardiovascular disease.
The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value.
This document was approved by the American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association in October 2018, and the American Heart Association Executive Committee in October 2018.
https://www.lipid.org/nla/national-lipid-association-releases-draft-part-two-its-recommendations-patient-centered The NLA Recommendations for Patient-Centered Management of Dyslipidemia, published in the Journal of Clinical Lipidology, re-affirm the importance of cholesterol goals for the prevention of heart attack and stroke. The recommendations should serve as guidance to clinicians for treating patients with dyslipidemia.
The National Lipid Association (NLA) recently convened an Expert Panel on Statin Safety to examine various aspects of statin therapy and to determine its safety, patient tolerance and effectiveness.
The NLA held a consensus conference in January 2011 to bring together experts on inflammatory markers and advanced lipoprotein testing for the generation of an NLA statement of clinical guidance regarding the utility of various biomarkers. The panel reviewed apolipoprotein B (Apo B), C-reactive protein (CRP), high-density lipoprotein (HDL) subfractions, lipoprotein-associated phospholipase A2 (Lp-PLA2), low-density lipoprotein (LDL) subfractions, low-density lipoprotein particle number/concentration (LDL-P), and lipoprotein (a) (Lp(a)).